Voltarol Emulgel 1% w/w Gel
*Company:
Haleon Ireland LimitedStatus:
No Recent UpdateLegal Category:
Supply through general saleActive Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 15 April 2024
File name
ie-text-pl-voltarol-002-clean- 240409KK - April 2024.pdf
Reasons for updating
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
Free text change information supplied by the pharmaceutical company
Updated due to the deletion of GSK CH GMBH & Co as a Batch Release Site.
Updated on 18 July 2023
File name
ie-pl-Voltarol-emulgel-1%ww-gel-proposed-clean-Jun2023.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
Updated on 18 July 2023
File name
ie-spc-Voltarol-emulgel-1%ww-gel-proposed-clean-Jun2023.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Legal category:Supply through general sale
Updated on 05 May 2022
File name
ie-mock-up-leaflet-RFI6-200727GLH.pdf
Reasons for updating
- Change to section 3 - dose and frequency
- Change to section 6 - date of revision
Updated on 05 May 2022
File name
APPROVED ie-spc-voltarol-emulgelp-pgsl-proposed-clean-dec2020.pdf
Reasons for updating
- Change to section 1 - Name of medicinal product
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
Legal category:Supply through general sale
Updated on 08 June 2020
File name
ie-spc-clean-PA0678140002-Apr2020xx.pdf
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Update the the SPC following approval of a safety variation.
Updated on 08 June 2020
File name
ie-mockup-leaflet-volt-emulgel-p-proposed-clean-mar2020.pdf
Reasons for updating
- Change to section 2 - what you need to know - contraindications
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - driving and using machines
- Change to section 2 - excipient warnings
- Change to section 5 - how to store or dispose
- Change to section 6 - what the product contains
- Change to MA holder contact details
Free text change information supplied by the pharmaceutical company
Contraindications
Addition of children under 14 years
Warnings
- Addition of flamabbility warning
- Remove of statement about concomitant use of NSAIDs
Driving
Removal of warning re dizziness
Excipients - warnings updated
Updated on 02 April 2020
File name
ie-spc-voltarenemulge1p-clean-proposed-feb2020.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
To update the duration of use to 14 days.
Updated on 25 March 2019
File name
ie-mockup-pl-voltarol-gel-proposed-jan2019.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 12 March 2019
File name
ie-mockup-pilx.pdf
Reasons for updating
- Change to section 6 - what the product looks like and pack contents
Updated on 12 March 2019
File name
ie-spc-0002-approved.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Additional of the no mess cap for the 100 g pack.
Updated on 12 March 2019
File name
ie-spc-0002-approved.pdf
Reasons for updating
- Change to section 6.5 - Nature and contents of container
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Change to add an additional cap on the 100g pack size to allow for consumers to apply the product without using their hands to rub it in.
Updated on 27 October 2016
File name
PIL_16710_671.pdf
Reasons for updating
- New PIL for new product
Updated on 27 October 2016
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - marketing authorisation number
Updated on 03 October 2016
Reasons for updating
- New SPC for new product
Legal category:Supply through general sale
Updated on 03 October 2016
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Updated on 03 May 2016
Reasons for updating
- New PIL for medicines.ie
Updated on 08 December 2014
Reasons for updating
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 6.5 - Nature and contents of container
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
The following has been added.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971; Fax: +353 1 6762517. Website: www.hpra.ie; E-mail: medsafety@hpra.ie.
In section: 6.5 Nature and contents of container
Pack sizes has been added, 50g & 100g.
Updated on 15 October 2014
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 4.4
“It should not be used with occlusion” added
Paragraph concerning excipients – slightly reworded
Section 7
Address changed to Camberley
Section 10
Date changed from Sept 2013 to August 2014
Updated on 16 September 2013
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 6.1 - List of excipients
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 2
Addition of benzyl benzoate to excipients list
Section 4.3
“isopropranol” changed to “isopropyl alcohol”
“Acetylsalicylic acid” changed to “aspirin”
Section 4.4
Under “Information concerning excipients” information added regarding irritant effect of benzyl benzoate.
Section 5.1
Section rewritten to include more information about mode of action and clinical data
Section 5.2
Section rewritten and split into subsections to include more information on absorption, distribution, biotransformation, elimination and activity in patients.
Section 5.3
Additional information added regarding preclinical experience with product.
Section 6.1
Addition of “(including benzyl benzoate)” after perfume.
Section 10
Date of revision changed from 16 November 2012 to 10 September 2013.
Updated on 20 December 2012
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 4.9 - Overdose
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 4.3
Add contraindications for last trimester of pregnancy and replace general statement about hypersensitivity to gel ingredients with specific statement referring to propylene glycol and isopropanol.
Section 4.4
Add “The possibility of systemic adverse events from application of Voltarol Emulgel P cannot be excluded if the preparation is used on large areas of skin and over a prolonged period (see the product information on systemic forms of diclofenac).”
Discontinue the treatment if a skin rash develops after applying the product.
Voltarol Emulgel P can be used with non-occlusive bandages but should not be used with an airtight occlusive dressing.”
and “Voltarol Emulgel P contains propylene glycol, which may cause mild localised skin irritation in some people.”
Delete “It should not be used with occlusion”. Replace “never be taken by mouth” with “not be ingested”
Section 4.5
Reword opening paragraph to “Since systemic absorption of diclofenac from topical application is very low, such interactions are very unlikely.”
Section 4.6
Change heading to “Fertility, pregnancy and lactation”
Previous information replaced with data to clarify recommendations associated with use in pregnancy and lactation, including contraindication in third trimester.
Section 4.7
Replace previous text with “Cutaneous application of Topical diclofenac has no influence on the ability to drive and use machines.”
Section 4.8
Frequencies for side effects have been added as per convention as well as table of reactions.
Section 4.9
Add “However, undesirable effects, similar to those observed following an overdose of diclofenac tablets, can be expected if Voltarol Emulgel P is inadvertently ingested (1 tube of 100g contains the equivalent of 1000mg of diclofenac sodium).”
Add “Gastric decontamination and the use of activated charcoal should be considered, especially within a short time of ingestion.”
Updated on 20 October 2011
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 4.2
Deletion of paragraph: Children: Not recommended
Addition of paragraph: Children and adolescents below 14 years: There are insufficient data on efficacy and safety available for children and adolescents below 14 years of age (see also contraindications section 4.3). In children aged 14 years and over, if this product is required for more than 7 days for pain relief or if the symptoms worsen the patient/parents of the adolescent is/are advised to consult a doctor.
Section 4.3
Addition of paragraph: The use in children and adolescents aged less than 14 years is contraindicated.
Section 9
Date of last renewal changed from 31 October 2008 to 17 October 2008.
Section 10
Date changed from October 2010 to October 2011
Updated on 11 January 2011
Reasons for updating
- Change to product name
- Change to section 1 - Name of medicinal product
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 5.3 - Preclinical safety data
- Change to section 6.4 - Special precautions for storage
- Change to section 6.5 - Nature and contents of container
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 1
Addition of ‘1% w/w Gel’.
Section 2
Addition of ‘Contains propylene glycol 5% w/w’. For full list of excipients see Section 6.1.
Section 4.2
New title added ‘Topical application’.
Section 4.5
Paragraph 1
The words ‘To date’ added at beginning of the paragraph.
Paragraph 2
The word ‘concentrations’ has been changed to ‘levels’.
Section 4.7
Paragraph: ‘Those who experience dizziness or other central nervous sytem disturbances, including visual disturbances, while taking NSAIDs should refrain from driving or operating machinery’ replaces ‘See side effects’.
Section 5.3
Addition of ‘Preclinical studies conducted with Voltarol Emulgel did not reveal any clinical relevant toxicological effects’ replaces ‘None known’.
Section 6.4
Wording changed from ‘Store below 30℃’ to ‘Do not store above 30℃’.
Section 6.5
Addition of words ‘available in packs of 10g and 30g’ at end of first paragraph.
Addition of words ‘available in packs of 30g’ at end of second paragraph.
Deletion of words ‘Both available in packs of 10g and 30g’.
Section 9
‘Date of first authorisation : 17 October 2003. Date of last renewal: 31 October 2008’ replaces’ 17 October 2003’.
Section 10
Date change from 29 September 2008 to October 2010.
Updated on 26 February 2009
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 6.6 - Special precautions for disposal and other handling
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Voltarol Emulgel P ROI- changes to SPC September 2008
Section 6.5: addition of description of colour of polypropylene screw cap white or blue
Section 6.6: change in section heading name from Instructions for Use/Handling to Special precautions for disposal
Section 10: revision date change from Aug 2007 to September 2008
Updated on 16 July 2008
Reasons for updating
- Change to section 6.5 - Nature and contents of container
- Change to section 9 - Date of renewal of authorisation
- Change to section 10 - Date of revision of the text
Legal category:Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 6.5: Further information added regarding the aluminium laminated tubes Section 9: Date of last renewal added
Section 10: Revision date changed
Updated on 10 August 2005
Reasons for updating
- New SPC for new product
Legal category:Supply through general sale